Molecular Imaging 2017

Phase II/III trials

Response Criteria in Solid Tumours: RECIST 1.1

 Response classification:  Complete remission (CR)  Partial remission (PR)  Stable disease (SD)  Progressive disease (PD) Validated response biomarker: Clinical trial end point that has proven useful for screening new therapeutic agents

Target lesions:  Longest dimension except nodes (short axis)

Eisenhauer et al. Eur J Cancer 2009;45:228-47 Therasse P et al. J Natl Cancer Inst 2000